Aprea Therapeutics, Inc. Revenue Not from Contract with Customer
Aprea Therapeutics, Inc. (APRE) reported Revenue Not from Contract with Customer of $285.76 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RevenueNotFromContractWithCustomer · last filed 2026-08-12
- Aprea Therapeutics, Inc. revenue not from contract with customer for the quarter ending 2025-12-31 was $3.34K, a 98.38% decline year-over-year.
- Aprea Therapeutics, Inc. revenue not from contract with customer for the quarter ending 2025-09-30 was $1.85K, a 99.48% decline year-over-year.
- Aprea Therapeutics, Inc. revenue not from contract with customer for the quarter ending 2025-06-30 was $118.11K, a 78.97% decline year-over-year.
- Aprea Therapeutics, Inc. revenue not from contract with customer for the quarter ending 2025-03-31 was $162.46K, a 57.31% decline year-over-year.
- Aprea Therapeutics, Inc. revenue not from contract with customer for fiscal 2025 was $285.76K, a 80.98% decline from fiscal 2024.
- Aprea Therapeutics, Inc. revenue not from contract with customer for fiscal 2024 was $1.50M, a 157.63% increase from fiscal 2023.
- Aprea Therapeutics, Inc. revenue not from contract with customer for fiscal 2023 was $583.23K.
| Period end | Revenue Not from Contract with Customer 3 month | Revenue Not from Contract with Customer 6 month | Revenue Not from Contract with Customer 9 month | Revenue Not from Contract with Customer 12 month |
|---|---|---|---|---|
| 2025-12-31 | $3.34K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $5.18K derived: sum of 2 quarters · filed 2026-03-16 | $123.30K derived: sum of 3 quarters · filed 2026-08-12 | $285.76K 10-K · filed 2026-03-16 |
| 2025-09-30 | $1.85K 10-Q · filed 2025-11-12 | $119.96K derived: sum of 2 quarters · filed 2026-08-12 | $282.42K 10-Q · filed 2025-11-12 | $488.24K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $118.11K 10-Q · filed 2026-08-12 | $280.57K 10-Q · filed 2026-08-12 | $486.39K derived: sum of 3 quarters · filed 2026-08-12 | $841.01K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $162.46K 10-Q · filed 2026-05-13 | $368.28K derived: sum of 2 quarters · filed 2026-05-13 | $722.90K derived: sum of 3 quarters · filed 2026-05-13 | $1.28M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $205.82K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $560.44K derived: sum of 2 quarters · filed 2026-03-16 | $1.12M derived: sum of 3 quarters · filed 2026-03-16 | $1.50M 10-K · filed 2026-03-16 |
| 2024-09-30 | $354.62K 10-Q · filed 2025-11-12 | $916.20K derived: sum of 2 quarters · filed 2025-11-12 | $1.30M 10-Q · filed 2025-11-12 | $1.31M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $561.57K 10-Q · filed 2025-08-12 | $942.14K 10-Q · filed 2025-08-12 | $956.22K derived: sum of 3 quarters · filed 2025-08-12 | $1.28M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $380.57K 10-Q · filed 2025-05-14 | $394.64K derived: sum of 2 quarters · filed 2025-05-14 | $714.11K derived: sum of 3 quarters · filed 2025-05-14 | $963.80K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $14.07K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $333.54K derived: sum of 2 quarters · filed 2025-03-25 | $583.23K derived: sum of 3 quarters · filed 2025-03-25 | $583.23K 10-K · filed 2025-03-25 |
| 2023-09-30 | $319.47K 10-Q · filed 2024-11-07 | $569.16K derived: sum of 2 quarters · filed 2024-11-07 | $569.16K 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $249.69K 10-Q · filed 2024-08-12 | $249.69K 10-Q · filed 2024-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |